RNA
Avidity Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.19
−2.81%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.87
- Revenue estimate
- $15.0M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$1.18
- EPS estimate
- -$1.42
- Revenue actual
- $3.0M
- Revenue estimate
- $666.7K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -1.3%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $25
- PT range
- $25 – $25
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026